Lung transplantation for cystic fibrosis: Results, indications, complications, and controversies

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 2, 2015, Pages 299-320

  Lynch, Joseph P ^a   Sayah, David M ^a   Belperio, John A ^a   Weigt, S Sam ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Burkholderia cepacia spp.; cystic fibrosis; lung transplant

Indexed keywords

ARTIFICIAL VENTILATION; ASPERGILLUS; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BRONCHIOLITIS OBLITERANS; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA CEPACIA INFECTION; COLON CANCER; CYSTIC FIBROSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; ENDOCRINE DISEASE; ESOPHAGUS CANCER; EXTRACORPOREAL OXYGENATION; GASTROINTESTINAL SYMPTOM; HEPATOBILIARY SYSTEM CANCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HISTORY OF MEDICINE; HUMAN; INFECTIOUS COMPLICATION; INVASIVE ASPERGILLOSIS; LUNG FIBROSIS; LUNG TRANSPLANTATION; LYMPHATIC LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; OPPORTUNISTIC INFECTION; PLEURA CAVITY; PNEUMONIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETRANSPLANTATION; REVIEW; SMALL INTESTINE CANCER; STENOTROPHOMONAS MALTOPHILIA; STOMACH CANCER; SURVIVAL; SYSTEMIC MYCOSIS; TESTIS CANCER; THORAX SURGERY; TRACHEOBRONCHITIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; MORTALITY; POSTOPERATIVE COMPLICATIONS;

CYSTIC FIBROSIS; HUMANS; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 84926225425     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0035-1547347     Document Type: Review

References (359)

1. Quon B. S., Aitken M. L. Cystic fibrosis: what to expect now in the early adult years. Paediatr Respir Rev: 2012; 13 4 206 214
2. Corris P. A. Lung transplantation for cystic fibrosis and bronchiectasis. Semin Respir Crit Care Med: 2013; 34 3 297 304
3. Reid D. W., Blizzard C. L., Shugg D. M., Flowers C., Cash C., Greville H. M. Changes in cystic fibrosis mortality in Australia, 1979-2005. Med J Aust: 2011; 195 7 392 395
4. Simmonds N. J. Ageing in cystic fibrosis and long-term survival. Paediatr Respir Rev: 2013; 14 01 6 9
5. Cystic Fibrosis Foundation Patient Registry. Annual Data Report. Cystic Fibrosis Foundation, Bethesda, MD; 2005
6. Dodge J. A., Lewis P. A., Stanton M., Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J: 2007; 29 3 522 526
7. Adler F. R., Aurora P., Barker D. H., et al. Lung transplantation for cystic fibrosis. Proc Am Thorac Soc: 2009; 6 8 619 633
8. Kotloff R. M., Thabut G. Lung transplantation. Am J Respir Crit Care Med: 2011; 184 2 159 171
9. Vizza C. D., Yusen R. D., Lynch J. P., Fedele F., Alexander Patterson G., Trulock E. P. Outcome of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med: 2000; 162 (3, Pt 1): 819 825
10. Sharples L., Hathaway T., Dennis C., Caine N., Higenbottam T., Wallwork J. Prognosis of patients with cystic fibrosis awaiting heart and lung transplantation. J Heart Lung Transplant: 1993; 12 4 669 674
11. Ciriaco P., Egan T. M., Cairns E. L., Thompson J. T., Detterbeck F. C., Paradowski L. J. Analysis of cystic fibrosis referrals for lung transplantation. Chest: 1995; 107 5 1323 1327
12. Stanchina M. L., Tantisira K. G., Aquino S. L., Wain J. C., Ginns L. C. Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. J Heart Lung Transplant: 2002; 21 2 217 225
13. Yusen R. D., Edwards L. B., Kucheryavaya A. Y., et al. International Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report-2014; focus theme: retransplantation. J Heart Lung Transplant: 2014; 33 10 1009 1024
14. Lanuza D. M., Lefaiver C., Mc Cabe M., Farcas G. A., Garrity E. Jr. Prospective study of functional status and quality of life before and after lung transplantation. Chest: 2000; 118 1 115 122
15. Durst C. L., Horn M. V., MacLaughlin E. F., Bowman C. M., Starnes V. A., Woo M. S. Psychosocial responses of adolescent cystic fibrosis patients to lung transplantation. Pediatr Transplant: 2001; 5 1 27 31
16. Vermeulen K. M., van der Bij W., Erasmus M. E., Duiverman E. J., Koëter G. H., TenVergert E. M. Improved quality of life after lung transplantation in individuals with cystic fibrosis. Pediatr Pulmonol: 2004; 37 5 419 426
17. Kugler C., Strueber M., Tegtbur U., Niedermeyer J., Haverich A. Quality of life 1 year after lung transplantation. Prog Transplant: 2004; 14 4 331 336
18. Yacoub M. H., Banner N. R., Khaghani A., et al. Heart-lung transplantation for cystic fibrosis and subsequent domino heart transplantation. J Heart Transplant: 1990; 9 5 459 466, discussion 466-467
19. de Leval M. R., Smyth R., Whitehead B., et al. Heart and lung transplantation for terminal cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg: 1991; 101 4 633 641, discussion 641-642
20. Vricella L. A., Karamichalis J. M., Ahmad S., Robbins R. C., Whyte R. I., Reitz B. A. Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the Stanford experience. Ann Thorac Surg: 2002; 74 1 13 17, discussion 17-18
21. Shennib H., Noirclerc M., Ernst P., et al. The Cystic Fibrosis Transplant Study Group. Double-lung transplantation for cystic fibrosis. Ann Thorac Surg: 1992; 54 1 27 31, discussion 31-32
22. Ganesh J. S., Rogers C. A., Bonser R. S., Banner N. R.; Steering Group of the UK Cardiothoracic Transplant Audit. Outcome of heart-lung and bilateral sequential lung transplantation for cystic fibrosis: a UK national study. Eur Respir J: 2005; 25 6 964 969
23. Egan T. M., Detterbeck F. C., Mill M. R., et al. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg: 2002; 22 4 602 609
24. Mendeloff E. N., Huddleston C. B., Mallory G. B., et al. Pediatric and adult lung transplantation for cystic fibrosis. J Thorac Cardiovasc Surg: 1998; 115 2 404 413, discussion 413-414
25. Spahr J. E., Love R. B., Francois M., Radford K., Meyer K. C. Lung transplantation for cystic fibrosis: current concepts and one center's experience. J Cyst Fibros: 2007; 6 5 334 350
26. Samano M. N., Pêgo-Fernandes P. M., Fonseca Ribeiro A. K., et al. Lung transplantation in patients with cystic fibrosis. Transplant Proc: 2013; 45 3 1137 1141
27. Diso D., Anile M., Patella M., et al. Lung transplantation for cystic fibrosis: outcome of 101 single-center consecutive patients. Transplant Proc: 2013; 45 1 346 348
28. Venuta F., Diso D., Anile M., et al. Evolving techniques and perspectives in lung transplantation. Transplant Proc: 2005; 37 6 2682 2683
29. Coloni G. F., Venuta F., Ciccone A. M., et al. Lung transplantation for cystic fibrosis. Transplant Proc: 2004; 36 3 648 650
30. Starnes V. A., Barr M. L., Cohen R. G., et al. Living-donor lobar lung transplantation experience: intermediate results. J Thorac Cardiovasc Surg: 1996; 112 5 1284 1290, discussion 1290-1291
31. Barr M. L., Schenkel F. A., Cohen R. G., et al. Recipient and donor outcomes in living related and unrelated lobar transplantation. Transplant Proc: 1998; 30 5 2261 2263
32. Woo M. S., MacLaughlin E. F., Horn M. V., et al. Living donor lobar lung transplantation: the pediatric experience. Pediatr Transplant: 1998; 2 3 185 190
33. Cohen R. G., Barr M. L., Schenkel F. A., DeMeester T. R., Wells W. J., Starnes V. A. Living-related donor lobectomy for bilateral lobar transplantation in patients with cystic fibrosis. Ann Thorac Surg: 1994; 57 6 1423 1427, discussion 1428
34. Starnes V. A., Bowdish M. E., Woo M. S., et al. A decade of living lobar lung transplantation: recipient outcomes. J Thorac Cardiovasc Surg: 2004; 127 1 114 122
35. Date H., Aoe M., Sano Y., et al. Improved survival after living-donor lobar lung transplantation. J Thorac Cardiovasc Surg: 2004; 128 6 933 940
36. Mitilian D., Sage E., Puyo P., et al. Foch Lung Transplant Group. Techniques and results of lobar lung transplantations. Eur J Cardiothorac Surg: 2014; 45 2 365 369, discussion 369-370
37. Inci I., Schuurmans M. M., Kestenholz P., et al. Long-term outcomes of bilateral lobar lung transplantation. Eur J Cardiothorac Surg: 2013; 43 6 1220 1225
38. Harring T. R., Nguyen N. T., Liu H., Karpen S. J., Goss J. A., O'Mahony C. A. Liver transplantation in cystic fibrosis: a report from Baylor College of Medicine and the Texas Children's Hospital. Pediatr Transplant: 2013; 17 3 271 277
39. Van De Wauwer C., Verschuuren E. A., Nossent G. D., et al. A staged approach for a lung-liver transplant patient using ex vivo reconditioned lungs first followed by an urgent liver transplantation. Transpl Int: 2015; 28 1 129 133
40. Borro J. M., Rama P., Rey T., Fernández-Rivera C. Long-term success of combined kidney-lung transplantation in a patient with cystic fibrosis. Arch Bronconeumol: 2013; 49 6 272 274
41. Orens J. B., Estenne M., Arcasoy S., et al. Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant: 2006; 25 7 745 755
42. Belkin R. A., Henig N. R., Singer L. G., et al. Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med: 2006; 173 6 659 666
43. Liou T. G., Woo M. S., Cahill B. C. Lung transplantation for cystic fibrosis. Curr Opin Pulm Med: 2006; 12 6 459 463
44. Hirche T. O., Knoop C., Hebestreit H., et al. ECORN-CF Study Group. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med: 2014; 2014 621342
45. Kerem E., Reisman J., Corey M., Canny G. J., Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med: 1992; 326 18 1187 1191
46. Rosenbluth D. B., Wilson K., Ferkol T., Schuster D. P. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest: 2004; 126 2 412 419
47. Milla C. E., Warwick W. J. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest: 1998; 113 5 1230 1234
48. Augarten A., Akons H., Aviram M., et al. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant: 2001; 5 5 339 342
49. Venuta F., Rendina E. A., De Giacomo T., et al. Timing and priorities for cystic fibrosis patients candidates to lung transplantation. Eur J Pediatr Surg: 1998; 8 5 274 277
50. Venuta F., Rendina E. A., Rocca G. D., et al. Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis. J Thorac Cardiovasc Surg: 2000; 119 (4, Pt 1): 682 689
51. Hayes D. Jr, Tobias J. D., Mansour H. M., et al. Pulmonary hypertension in cystic fibrosis with advanced lung disease. Am J Respir Crit Care Med: 2014; 190 8 898 905
52. Tuppin M. P., Paratz J. D., Chang A. T., et al. Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant: 2008; 27 7 729 734
53. Mayer-Hamblett N., Rosenfeld M., Emerson J., Goss C. H., Aitken M. L. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med: 2002; 166 (12, Pt 1): 1550 1555
54. Ellaffi M., Vinsonneau C., Coste J., et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med: 2005; 171 2 158 164
55. Hayes D. Jr, Higgins R. S., Kirkby S., et al. Impact of pulmonary hypertension on survival in patients with cystic fibrosis undergoing lung transplantation: an analysis of the UNOS registry. J Cyst Fibros: 2014; 13 4 416 423
56. Flume P. A. Pneumothorax in cystic fibrosis. Chest: 2003; 123 1 217 221
57. Smyth R. L., Scott J. P., McGoldrick J. P., Higenbottam T. W., Wallwork J. Heart-lung transplantation for pneumothorax in cystic fibrosis. Ann Thorac Surg: 1989; 48 5 744 745
58. Curtis H. J., Bourke S. J., Dark J. H., Corris P. A. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant: 2005; 24 7 865 869
59. Detterbeck F. C., Egan T. M., Mill M. R. Lung transplantation after previous thoracic surgical procedures. Ann Thorac Surg: 1995; 60 1 139 143
60. Rolla M., Anile M., Venuta F., et al. Lung transplantation for cystic fibrosis after thoracic surgical procedures. Transplant Proc: 2011; 43 4 1162 1163
61. Dusmet M., Winton T. L., Kesten S., Maurer J. Previous intrapleural procedures do not adversely affect lung transplantation. J Heart Lung Transplant: 1996; 15 3 249 254
62. Elizur A., Sweet S. C., Huddleston C. B., et al. Pre-transplant mechanical ventilation increases short-term morbidity and mortality in pediatric patients with cystic fibrosis. J Heart Lung Transplant: 2007; 26 2 127 131
63. Efrati O., Bylin I., Segal E., et al. Outcome of patients with cystic fibrosis admitted to the intensive care unit: is invasive mechanical ventilation a risk factor for death in patients waiting lung transplantation? Heart Lung: 2010; 39 2 153 159
64. Bartz R. R., Love R. B., Leverson G. E., Will L. R., Welter D. L., Meyer K. C. Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis. J Heart Lung Transplant: 2003; 22 4 433 438
65. Massard G., Shennib H., Metras D., et al. Double-lung transplantation in mechanically ventilated patients with cystic fibrosis. Ann Thorac Surg: 1993; 55 5 1087 1091, discussion 1091-1092
66. Sood N., Paradowski L. J., Yankaskas J. R. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med: 2001; 163 2 335 338
67. Flume P. A., Egan T. M., Westerman J. H., et al. Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant: 1994; 13 (1, Pt 1): 15 21, discussion 22-23
68. Mason D. P., Thuita L., Nowicki E. R., Murthy S. C., Pettersson G. B., Blackstone E. H. Should lung transplantation be performed for patients on mechanical respiratory support? The US experience. J Thorac Cardiovasc Surg: 2010; 139 3 765 773.e1
69. Singer J. P., Blanc P. D., Hoopes C., et al. The impact of pretransplant mechanical ventilation on short- and long-term survival after lung transplantation. Am J Transplant: 2011; 11 10 2197 2204
70. Lang G., Taghavi S., Aigner C., et al. Primary lung transplantation after bridge with extracorporeal membrane oxygenation: a plea for a shift in our paradigms for indications. Transplantation: 2012; 93 7 729 736
71. Casswell G. K., Pilcher D. V., Martin R. S., et al. Buying time: The use of extracorporeal membrane oxygenation as a bridge to lung transplantation in pediatric patients. Pediatr Transplant: 2013; 17 8 E182 E188
72. Anile M., Diso D., Russo E., et al. Extracorporeal membrane oxygenation as bridge to lung transplantation. Transplant Proc: 2013; 45 7 2621 2623
73. Lafarge M., Mordant P., Thabut G., et al. Experience of extracorporeal membrane oxygenation as a bridge to lung transplantation in France. J Heart Lung Transplant: 2013; 32 9 905 913
74. Toyoda Y., Bhama J. K., Shigemura N., et al. Efficacy of extracorporeal membrane oxygenation as a bridge to lung transplantation. J Thorac Cardiovasc Surg: 2013; 145 4 1065 1070, discussion 1070-1071
75. Garcia J. P., Kon Z. N., Evans C., et al. Ambulatory veno-venous extracorporeal membrane oxygenation: innovation and pitfalls. J Thorac Cardiovasc Surg: 2011; 142 4 755 761
76. Fuehner T., Kuehn C., Hadem J., et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med: 2012; 185 7 763 768
77. Olsson K. M., Simon A., Strueber M., et al. Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation. Am J Transplant: 2010; 10 9 2173 2178
78. Schmidt F., Sasse M., Boehne M., et al. Concept of awake venovenous extracorporeal membrane oxygenation in pediatric patients awaiting lung transplantation. Pediatr Transplant: 2013; 17 3 224 230
79. Hayes D. Jr, Kukreja J., Tobias J. D., Ballard H. O., Hoopes C. W. Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation. J Cyst Fibros: 2012; 11 1 40 45
80. Hayes D. Jr, Galantowicz M., Yates A. R., Preston T. J., Mansour H. M., McConnell P. I. Venovenous ECMO as a bridge to lung transplant and a protective strategy for subsequent primary graft dysfunction. J Artif Organs: 2013; 16 3 382 385
81. Kirkby S., Whitson B. A., Wehr A. M., Lehman A. M., Higgins R. S., Hayes D. Jr. Survival benefit of induction immunosuppression in cystic fibrosis lung transplant recipients. J Cyst Fibros: 2015; 14 1 104 110
82. Liou T. G., Adler F. R., Fitzsimmons S. C., Cahill B. C., Hibbs J. R., Marshall B. C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol: 2001; 153 4 345 352
83. Liou T. G., Adler F. R., Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med: 2005; 171 9 1053 1059
84. Kirkby S., Hayes D. Jr. Pediatric lung transplantation: indications and outcomes. J Thorac Dis: 2014; 6 8 1024 1031
85. Thabut G., Christie J. D., Mal H., et al. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. Am J Respir Crit Care Med: 2013; 187 12 1335 1340
86. Lobo L. J., Noone P. G. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med: 2014; 2 73 82
87. Remund K. F., Best M., Egan J. J. Infections relevant to lung transplantation. Proc Am Thorac Soc: 2009; 6 1 94 100
88. Dorgan D. J., Hadjiliadis D. Lung transplantation in patients with cystic fibrosis: special focus to infection and comorbidities. Expert Rev Respir Med: 2014; 8 3 315 326
89. Robertson J. M., Friedman E. M., Rubin B. K. Nasal and sinus disease in cystic fibrosis. Paediatr Respir Rev: 2008; 9 3 213 219
90. Rosbe K. W., Jones D. T., Rahbar R., Lahiri T., Auerbach A. D. Endoscopic sinus surgery in cystic fibrosis: do patients benefit from surgery? Int J Pediatr Otorhinolaryngol: 2001; 61 2 113 119
91. Mainz J. G., Hentschel J., Schien C., et al. Sinonasal persistence of Pseudomonas aeruginosa after lung transplantation. J Cyst Fibros: 2012; 11 2 158 161
92. Aanæs K. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. J Cyst Fibros: 2013; 12 02 S1 S20
93. Ciofu O., Johansen H. K., Aanaes K., et al. P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs. J Cyst Fibros: 2013; 12 6 729 736
94. Mainz J. G., Naehrlich L., Schien M., et al. Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax: 2009; 64 6 535 540
95. Holzmann D., Speich R., Kaufmann T., et al. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience. Transplantation: 2004; 77 1 134 136
96. Flume P. A., Egan T. M., Paradowski L. J., Detterbeck F. C., Thompson J. T., Yankaskas J. R. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med: 1994; 149 6 1601 1607
97. Kanj S. S., Tapson V., Davis R. D., Madden J., Browning I. Infections in patients with cystic fibrosis following lung transplantation. Chest: 1997; 112 4 924 930
98. Razvi S., Quittell L., Sewall A., Quinton H., Marshall B., Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest: 2009; 136 6 1554 1560
99. Millar F. A., Simmonds N. J., Hodson M. E. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros: 2009; 8 6 386 391
100. Li Z., Kosorok M. R., Farrell P. M., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA: 2005; 293 5 581 588
101. Nunley D. R., Grgurich W., Iacono A. T., et al. Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest: 1998; 113 5 1235 1243
102. Bonvillain R. W., Valentine V. G., Lombard G., LaPlace S., Dhillon G., Wang G. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transplant: 2007; 26 9 890 897
103. Walter S., Gudowius P., Bosshammer J., et al. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax: 1997; 52 4 318 321
104. Haja Mydin H., Corris P. A., Nicholson A., et al. Targeted antibiotic prophylaxis for lung transplantation in cystic fibrosis patients colonised with Pseudomonas aeruginosa using multiple combination bactericidal testing. J Transplant: 2012; 2012 135738
105. Pitt T. L., Sparrow M., Warner M., Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax: 2003; 58 9 794 796
106. Perry J. D., Laine L., Hughes S., Nicholson A., Galloway A., Gould F. K. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J Antimicrob Chemother: 2008; 61 5 1057 1061
107. Dales L., Ferris W., Vandemheen K., Aaron S. D. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis: 2009; 28 10 1275 1279
108. Hadjiliadis D., Steele M. P., Chaparro C., et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant: 2007; 26 8 834 838
109. Dobbin C., Maley M., Harkness J., et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect: 2004; 56 4 277 282
110. Aris R. M., Gilligan P. H., Neuringer I. P., Gott K. K., Rea J., Yankaskas J. R. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med: 1997; 155 5 1699 1704
111. Lang B. J., Aaron S. D., Ferris W., Hebert P. C., MacDonald N. E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med: 2000; 162 6 2241 2245
112. Aaron S. D., Vandemheen K. L., Ferris W., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet: 2005; 366 9484 463 471
113. Suhling H., Rademacher J., Greer M., et al. Inhaled colistin following lung transplantation in colonised cystic fibrosis patients. Eur Respir J: 2013; 42 2 542 544
114. Botha P., Archer L., Anderson R. L., et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation: 2008; 85 5 771 774
115. Vos R., Vanaudenaerde B. M., Geudens N., Dupont L. J., Van Raemdonck D. E., Verleden G. M. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J: 2008; 31 5 1037 1045
116. Waters V., Atenafu E. G., Lu A., Yau Y., Tullis E., Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros: 2013; 12 5 482 486
117. Stanojevic S., Ratjen F., Stephens D., et al. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros: 2013; 12 6 575 583
118. Lynch J. P. III. Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion. Semin Respir Crit Care Med: 2009; 30 5 596 610
119. LiPuma J. J. Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med: 2003; 24 6 681 692
120. Chaparro C., Maurer J., Gutierrez C., et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med: 2001; 163 1 43 48
121. Alexander B. D., Petzold E. W., Reller L. B., et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant: 2008; 8 5 1025 1030
122. Coenye T., Vandamme P., Govan J. R., LiPuma J. J. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol: 2001; 39 10 3427 3436
123. Chen J. S., Witzmann K. A., Spilker T., Fink R. J., LiPuma J. J. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr: 2001; 139 5 643 649
124. Coenye T., Spilker T., Van Schoor A., LiPuma J. J., Vandamme P. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax: 2004; 59 11 952 954
125. Holden M. T., Seth-Smith H. M., Crossman L. C., et al. The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol: 2009; 191 1 261 277
126. Jones A. M., Dodd M. E., Govan J. R., et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax: 2004; 59 11 948 951
127. Mahenthiralingam E., Vandamme P., Campbell M. E., et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis: 2001; 33 9 1469 1475
128. Aris R. M., Routh J. C., LiPuma J. J., Heath D. G., Gilligan P. H. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med: 2001; 164 11 2102 2106
129. Murray S., Charbeneau J., Marshall B. C., LiPuma J. J. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med: 2008; 178 4 363 371
130. Frangolias D. D., Mahenthiralingam E., Rae S., et al. Burkholderia cepacia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med: 1999; 160 (5, Pt 1): 1572 1577
131. Manno G., Dalmastri C., Tabacchioni S., et al. Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center. J Clin Microbiol: 2004; 42 4 1491 1497
132. Tablan O. C., Martone W. J., Doershuk C. F., et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest: 1987; 91 4 527 532
133. Kalish L. A., Waltz D. A., Dovey M., et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med: 2006; 173 4 421 425
134. Ledson M. J., Gallagher M. J., Jackson M., Hart C. A., Walshaw M. J. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax: 2002; 57 2 142 145
135. Muhdi K., Edenborough F. P., Gumery L., et al. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax: 1996; 51 4 374 377
136. Lewin L. O., Byard P. J., Davis P. B. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol: 1990; 43 2 125 131
137. De Soyza A., Archer L., Wardle J., et al. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. J Heart Lung Transplant: 2003; 22 7 764 769
138. Meachery G., De Soyza A., Nicholson A., et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax: 2008; 63 8 725 731
139. De Soyza A., Meachery G., Hester K. L., et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant: 2010; 29 12 1395 1404
140. Snell G. I., de Hoyos A., Krajden M., Winton T., Maurer J. R. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest: 1993; 103 2 466 471
141. De Soyza A., McDowell A., Archer L., et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet: 2001; 358 9295 1780 1781
142. Egan J. J., McNeil K., Bookless B., et al. Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia. Lancet: 1994; 344 8921 552 553
143. Savi D., De Biase R. V., Amaddeo A., et al. Burkholderia pyrrocinia in cystic fibrosis lung transplantation: a case report. Transplant Proc: 2014; 46 1 295 297
144. de Perrot M., Chaparro C., McRae K., et al. Twenty-year experience of lung transplantation at a single center: Influence of recipient diagnosis on long-term survival. J Thorac Cardiovasc Surg: 2004; 127 5 1493 1501
145. Boussaud V., Guillemain R., Grenet D., et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax: 2008; 63 8 732 737
146. Aaron S. D., Ferris W., Henry D. A., Speert D. P., Macdonald N. E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med: 2000; 161 (4, Pt 1): 1206 1212
147. Zhou J., Chen Y., Tabibi S., Alba L., Garber E., Saiman L. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother: 2007; 51 3 1085 1088
148. Lewin C., Doherty C., Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother: 1993; 37 1 123 125
149. Manno G., Ugolotti E., Belli M. L., Fenu M. L., Romano L., Cruciani M. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis: 2003; 22 1 28 34
150. Avgeri S. G., Matthaiou D. K., Dimopoulos G., Grammatikos A. P., Falagas M. E. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents: 2009; 33 5 394 404
151. Tullis D. E., Burns J. L., Retsch-Bogart G. Z., et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros: 2014; 13 3 296 305
152. Woods C. W., Bressler A. M., LiPuma J. J., et al. Virulence associated with outbreak-related strains of Burkholderia cepacia complex among a cohort of patients with bacteremia. Clin Infect Dis: 2004; 38 9 1243 1250
153. Mahenthiralingam E., Baldwin A., Dowson C. G. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J Appl Microbiol: 2008; 104 6 1539 1551
154. Govan J. R., Brown P. H., Maddison J., et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet: 1993; 342 8862 15 19
155. Clode F. E., Kaufmann M. E., Malnick H., Pitt T. L. Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom. J Clin Microbiol: 2000; 38 5 1763 1766
156. France M. W., Dodd M. E., Govan J. R., Doherty C. J., Webb A. K., Jones A. M. The changing epidemiology of Burkholderia species infection at an adult cystic fibrosis centre. J Cyst Fibros: 2008; 7 5 368 372
157. Koch C., Frederiksen B., Hoiby N. Patient cohorting and infection control. Semin Respir Crit Care Med: 2003; 24 6 703 716
158. McDowell A., Mahenthiralingam E., Dunbar K. E., Moore J. E., Crowe M., Elborn J. S. Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation. J Med Microbiol: 2004; 53 Pt 7 663 668
159. Johansen H. K., Kovesi T. A., Koch C., Corey M., Hoiby N., Levison H. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol: 1998; 26 2 89 96
160. Saiman L., Macdonald N., Burns J. L., Hoiby N., Speert D. P., Weber D. Infection control in cystic fibrosis: practical recommendations for the hospital, clinic, and social settings. Am J Infect Control: 2000; 28 5 381 385
161. Conway S. Segregation is good for patients with cystic fibrosis. J R Soc Med: 2008; 101 01 S31 S35
162. Paul M. L., Pegler M. A., Benn R. A. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centres. J Hosp Infect: 1998; 38 1 19 26
163. Solé A., Salavert M. Fungal infections after lung transplantation. Transplant Rev (Orlando): 2008; 22 2 89 104
164. Nunley D. R., Ohori P., Grgurich W. F., et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest: 1998; 114 5 1321 1329
165. Liu M., Worley S., Mallory G. B. Jr., et al. Fungal infections in pediatric lung transplant recipients: colonization and invasive disease. J Heart Lung Transplant: 2009; 28 11 1226 1230
166. Iversen M., Burton C. M., Vand S., et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis: 2007; 26 12 879 886
167. Singh N., Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant: 2003; 22 3 258 266
168. Cahill B. C., Hibbs J. R., Savik K., et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest: 1997; 112 5 1160 1164
169. Mehrad B., Paciocco G., Martinez F. J., Ojo T. C., Iannettoni M. D., Lynch J. P. III. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest: 2001; 119 1 169 175
170. Minari A., Husni R., Avery R. K., et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis: 2002; 4 4 195 200
171. Solé A., Morant P., Salavert M., Pemán J., Morales P. Valencia Lung Transplant Group Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect: 2005; 11 5 359 365
172. Paterson D. L., Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore): 1999; 78 2 123 138
173. Liu J. C., Modha D. E., Gaillard E. A. What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis? J Cyst Fibros: 2013; 12 3 187 193
174. Helmi M., Love R. B., Welter D., Cornwell R. D., Meyer K. C. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest: 2003; 123 3 800 808
175. Luong M. L., Chaparro C., Stephenson A., et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation: 2014; 97 3 351 357
176. de Vrankrijker A. M., van der Ent C. K., van Berkhout F. T., et al. Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function? Clin Microbiol Infect: 2011; 17 9 1381 1386
177. Egan J. J., Yonan N., Carroll K. B., Deiraniya A. K., Webb A. K., Woodcock A. A. Allergic bronchopulmonary aspergillosis in lung allograft recipients. Eur Respir J: 1996; 9 1 169 171
178. Jubin V., Ranque S., Stremler Le Bel N., Sarles J., Dubus J. C. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol: 2010; 45 8 764 771
179. Paugam A., Baixench M. T., Demazes-Dufeu N., et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol: 2010; 48 01 S32 S36
180. Shoseyov D., Brownlee K. G., Conway S. P., Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest: 2006; 130 1 222 226
181. Pappas P. G., Alexander B. D., Andes D. R., et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis: 2010; 50 8 1101 1111
182. Bhaskaran A., Hosseini-Moghaddam S. M., Rotstein C., Husain S. Mold infections in lung transplant recipients. Semin Respir Crit Care Med: 2013; 34 3 371 379
183. Husni R. N., Gordon S. M., Longworth D. L., et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis: 1998; 26 3 753 755
184. Husain S., Paterson D. L., Studer S., et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant: 2006; 6 12 3008 3016
185. Westney G. E., Kesten S., De Hoyos A., Chapparro C., Winton T., Maurer J. R. Aspergillus infection in single and double lung transplant recipients. Transplantation: 1996; 61 6 915 919
186. Goldfarb N. S., Avery R. K., Goormastic M., et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation: 2001; 71 2 242 246
187. Mead L., Danziger-Isakov L. A., Michaels M. G., Goldfarb S., Glanville A. R., Benden C.; International Pediatric Lung Transplant Collaborative (IPLTC). Antifungal prophylaxis in pediatric lung transplantation: an international multicenter survey. Pediatr Transplant: 2014; 18 4 393 397
188. Avery R. K. Antifungal prophylaxis in lung transplantation. Semin Respir Crit Care Med: 2011; 32 6 717 726
189. Kramer M. R., Denning D. W., Marshall S. E., et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis: 1991; 144 3, Pt 1 552 556
190. Wu N., Huang Y., Li Q., Bai C., Huang H. D., Yao X. P. Isolated invasive Aspergillus tracheobronchitis: a clinical study of 19 cases. Clin Microbiol Infect: 2010; 16 6 689 695
191. Nunley D. R., Gal A. A., Vega J. D., Perlino C., Smith P., Lawrence E. C. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest: 2002; 122 4 1185 1191
192. Fernández-Ruiz M., Silva J. T., San-Juan R., et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore): 2012; 91 5 261 273
193. Neofytos D., Fishman J. A., Horn D., et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis: 2010; 12 3 220 229
194. Pihet M., Carrere J., Cimon B., et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis-a review. Med Mycol: 2009; 47 4 387 397
195. Park S. Y., Kim S. H., Choi S. H., et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis: 2010; 12 4 309 315
196. Husain S., Kwak E. J., Obman A., et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant: 2004; 4 5 796 802
197. Husain S., Paterson D. L., Studer S. M., et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation: 2007; 83 10 1330 1336
198. Luong M. L., Clancy C. J., Vadnerkar A., et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis: 2011; 52 10 1218 1226
199. Hadjiliadis D., Sporn T. A., Perfect J. R., Tapson V. F., Davis R. D., Palmer S. M. Outcome of lung transplantation in patients with mycetomas. Chest: 2002; 121 1 128 134
200. Billaud E. M., Guillemain R., Berge M., et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol: 2010; 48 01 S52 S59
201. Han K., Capitano B., Bies R., et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother: 2010; 54 10 4424 4431
202. Thompson G. R. III, Patterson T. F. Pulmonary aspergillosis: recent advances. Semin Respir Crit Care Med: 2011; 32 6 673 681
203. Baddley J. W., Andes D. R., Marr K. A., et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis: 2010; 50 12 1559 1567
204. Steinbach W. J., Marr K. A., Anaissie E. J., et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect: 2012; 65 5 453 464
205. Herbrecht R., Denning D. W., Patterson T. F., et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med: 2002; 347 6 408 415
206. Singh N., Limaye A. P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation: 2006; 81 3 320 326
207. Walsh T. J., Anaissie E. J., Denning D. W., et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis: 2008; 46 3 327 360
208. Steinbach W. J., Stevens D. A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis: 2003; 37 03 S157 S187
209. Chen J., Chan C., Colantonio D., Seto W. Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit: 2012; 34 1 77 84
210. Brett J., Chong O., Graham G. G., et al. Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients. Ther Drug Monit: 2013; 35 1 133 136
211. Mitsani D., Nguyen M. H., Shields R. K., et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother: 2012; 56 5 2371 2377
212. Viscoli C., Herbrecht R., Akan H., et al. Infectious Disease Group of the EORTC. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother: 2009; 64 6 1274 1281
213. Hiemenz J. W., Raad I. I., Maertens J. A., et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis: 2010; 29 11 1387 1394
214. Heinz W. J., Egerer G., Lellek H., Boehme A., Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive Aspergillus disease, a retrospective analysis. Mycoses: 2013; 56 3 304 310
215. Ullmann A. J., Lipton J. H., Vesole D. H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med: 2007; 356 4 335 347
216. Cornely O. A., Maertens J., Winston D. J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med: 2007; 356 4 348 359
217. Mihu C. N., Kassis C., Ramos E. R., Jiang Y., Hachem R. Y., Raad I. I. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer: 2010; 116 22 5290 5296
218. Weigt S. S., Elashoff R. M., Huang C., et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant: 2009; 9 8 1903 1911
219. Weigt S. S., Copeland C. A., Derhovanessian A., et al. Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study. Am J Transplant: 2013; 13 4 919 927
220. Husain S., Zaldonis D., Kusne S., Kwak E. J., Paterson D. L., McCurry K. R. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis: 2006; 8 4 213 218
221. Neoh C. F., Snell G. I., Kotsimbos T., et al. Antifungal prophylaxis in lung transplantation-a world-wide survey. Am J Transplant: 2011; 11 2 361 366
222. Schaenman J. M. Is universal antifungal prophylaxis mandatory in lung transplant patients? Curr Opin Infect Dis: 2013; 26 4 317 325
223. Tofte N., Jensen C., Tvede M., Andersen C. B., Carlsen J., Iversen M. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients. Scand J Infect Dis: 2012; 44 11 835 841
224. Reichenspurner H., Gamberg P., Nitschke M., et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc: 1997; 29 1-2 627 628
225. Drew R. H., Dodds Ashley E., Benjamin D. K. Jr, Duane Davis R., Palmer S. M., Perfect J. R. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation: 2004; 77 2 232 237
226. Monforte V., Ussetti P., Gavaldà J., et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant: 2010; 29 5 523 530
227. Cadena J., Levine D. J., Angel L. F., et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant: 2009; 9 9 2085 2091
228. Lowry C. M., Marty F. M., Vargas S. O., et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis: 2007; 9 2 121 125
229. Eriksson M., Lemström K., Suojaranta-Ylinen R., et al. Control of early Aspergillus mortality after lung transplantation: outcome and risk factors. Transplant Proc: 2010; 42 10 4459 4464
230. Koo S., Kubiak D. W., Issa N. C., et al. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation: 2012; 94 3 281 286
231. Singh N., Husain S.; AST Infectious Diseases Community of Practice. Aspergillosis in solid organ transplantation. Am J Transplant: 2013; 13 04 228 241
232. Zwald F. O., Spratt M., Lemos B. D., et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg: 2012; 38 8 1369 1374
233. Vadnerkar A., Nguyen M. H., Mitsani D., et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant: 2010; 29 11 1240 1244
234. Singer J. P., Boker A., Metchnikoff C., et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant: 2012; 31 7 694 699
235. Palmer S. M., Perfect J. R., Howell D. N., et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant: 1998; 17 10 1029 1033
236. Hadjiliadis D., Howell D. N., Davis R. D., et al. Anastomotic infections in lung transplant recipients. Ann Transplant: 2000; 5 3 13 19
237. Almyroudis N. G., Sutton D. A., Linden P., Rinaldi M. G., Fung J., Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant: 2006; 6 10 2365 2374
238. Neofytos D., Treadway S., Ostrander D., et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis: 2013; 15 3 233 242
239. Quan C., Spellberg B. Mucormycosis, pseudallescheriasis, and other uncommon mold infections. Proc Am Thorac Soc: 2010; 7 3 210 215
240. Neto F. M., Camargo P. C., Costa A. N., et al. Fungal infection by Mucorales order in lung transplantation: 4 case reports. Transplant Proc: 2014; 46 6 1849 1851
241. Herbrecht R., Kessler R., Kravanja C., Meyer M. H., Waller J., Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant: 2004; 23 12 1451 1454
242. Sampathkumar P., Paya C. V. Fusarium infection after solid-organ transplantation. Clin Infect Dis: 2001; 32 8 1237 1240
243. Tamm M., Malouf M., Glanville A. Pulmonary scedosporium infection following lung transplantation. Transpl Infect Dis: 2001; 3 4 189 194
244. Musk M., Chambers D., Chin W., Murray R., Gabbay E. Successful treatment of disseminated scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant: 2006; 25 10 1268 1272
245. Raj R., Frost A. E. Scedosporium apiospermum fungemia in a lung transplant recipient. Chest: 2002; 121 5 1714 1716
246. Symoens F., Knoop C., Schrooyen M., et al. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant: 2006; 25 5 603 607
247. Morio F., Horeau-Langlard D., Gay-Andrieu F., et al. Disseminated Scedosporium/Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis. J Clin Microbiol: 2010; 48 5 1978 1982
248. Castiglioni B., Sutton D. A., Rinaldi M. G., Fung J., Kusne S. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore): 2002; 81 5 333 348
249. Cimon B., Carrère J., Vinatier J. F., Chazalette J. P., Chabasse D., Bouchara J. P. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis: 2000; 19 1 53 56
250. Hartmann C., Müller C., Weibrodt H., et al. Successful prevention of scedosporiosis after lung transplantation in a cystic fibrosis patient by combined local and systemic triazole therapy. Med Mycol Case Rep: 2013; 2 116 118
251. Russell G. K., Gadhok R., Simmonds N. J. The destructive combination of Scediosporium apiosperum lung disease and exuberant inflammation in cystic fibrosis. Paediatr Respir Rev: 2013; 14 01 22 25
252. Hamilos G., Samonis G., Kontoyiannis D. P. Pulmonary mucormycosis. Semin Respir Crit Care Med: 2011; 32 6 693 702
253. Cavusoglu C., Cicek-Saydam C., Karasu Z., et al. Mycobacterium tuberculosis infection and laboratory diagnosis in solid-organ transplant recipients. Clin Transplant: 2002; 16 4 257 261
254. Shitrit D., Bendayan D., Saute M., Kramer M. R. Multidrug resistant tuberculosis following lung transplantation: treatment with pulmonary resection. Thorax: 2004; 59 1 79 80
255. Malouf M. A., Glanville A. R. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med: 1999; 160 (5, Pt 1): 1611 1616
256. Lee J., Yew W. W., Wong C. F., Wong P. C., Chiu C. S. Multidrug-resistant tuberculosis in a lung transplant recipient. J Heart Lung Transplant: 2003; 22 10 1168 1173
257. Singh N., Paterson D. L. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis: 1998; 27 5 1266 1277
258. Muñoz P., Rodríguez C., Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis: 2005; 40 4 581 587
259. Miller R. A., Lanza L. A., Kline J. N., Geist L. J. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med: 1995; 152 1 374 376
260. Aguilar-Guisado M., Givaldá J., Ussetti P., et al. RESITRA cohort. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant: 2007; 7 8 1989 1996
261. Olivier K. N., Weber D. J., Lee J. H., et al. Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med: 2003; 167 6 835 840
262. Olivier K. N., Weber D. J., Wallace R. J. Jr., et al. Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med: 2003; 167 6 828 834
263. Leung J. M., Olivier K. N. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med: 2013; 34 1 124 134
264. Oliver A., Maiz L., Cantón R., Escobar H., Baquero F., Gómez-Mampaso E. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis: 2001; 32 9 1298 1303
265. Razvi S., Saiman L. Nontuberculous mycobacteria in cystic fibrosis. Pediatr Infect Dis J: 2007; 26 3 263 264
266. Levy I., Grisaru-Soen G., Lerner-Geva L., et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis: 2008; 14 3 378 384
267. Bar-On O., Mussaffi H., Mei-Zahav M., et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros: 2015; 14 1 53 62
268. Qvist T., Gilljam M., Jonsson B., et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros: 2015; 14 1 46 52
269. Chernenko S. M., Humar A., Hutcheon M., et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant: 2006; 25 12 1447 1455
270. Kesten S., Chaparro C. Mycobacterial infections in lung transplant recipients. Chest: 1999; 115 3 741 745
271. Chalermskulrat W., Sood N., Neuringer I. P., et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax: 2006; 61 6 507 513
272. Huang H. C., Weigt S. S., Derhovanessian A., et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant: 2011; 30 7 790 798
273. Sermet-Gaudelus I., Le Bourgeois M., Pierre-Audigier C., et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis: 2003; 9 12 1587 1591
274. Roux A. L., Catherinot E., Ripoll F., et al. Jean-Louis Herrmann for the OMA Group. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol: 2009; 47 12 4124 4128
275. Hjelte L., Petrini B., Källenius G., Strandvik B. Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax: 1990; 45 5 397 400
276. Whittaker L. A., Teneback C. Atypical mycobacterial and fungal infections in cystic fibrosis. Semin Respir Crit Care Med: 2009; 30 5 539 546
277. Efthimiou J., Smith M. J., Hodson M. E., Batten J. C. Fatal pulmonary infection with Mycobacterium fortuitum in cystic fibrosis. Br J Dis Chest: 1984; 78 3 299 302
278. Fairhurst R. M., Kubak B. M., Shpiner R. B., Levine M. S., Pegues D. A., Ardehali A. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant: 2002; 21 3 391 394
279. Sanguinetti M., Ardito F., Fiscarelli E., et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol: 2001; 39 2 816 819
280. Doucette K., Fishman J. A. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis: 2004; 38 10 1428 1439
281. Torres F., Hodges T., Zamora M. R. Mycobacterium marinum infection in a lung transplant recipient. J Heart Lung Transplant: 2001; 20 4 486 489
282. Taylor J. L., Palmer S. M. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant: 2006; 25 8 985 988
283. Muñoz R. M., Alonso-Pulpón L., Yebra M., Segovia J., Gallego J. C., Daza R. M. Intestinal involvement by nontuberculous mycobacteria after heart transplantation. Clin Infect Dis: 2000; 30 3 603 605
284. Griffith D. E., Aksamit T., Brown-Elliott B. A., et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med: 2007; 175 4 367 416
285. Sugihara E., Hirota N., Niizeki T., et al. Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by Mycobacterium avium-intracellulare complex (MAC) infection. J Infect Chemother: 2003; 9 4 328 332
286. Koh W. J., Lee K. S., Kwon O. J., Jeong Y. J., Kwak S. H., Kim T. S. Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. Radiology: 2005; 235 1 282 288
287. Ellis S. M. The spectrum of tuberculosis and non-tuberculous mycobacterial infection. Eur Radiol: 2004; 14 03 E34 E42
288. Trulock E. P., Bolman R. M., Genton R. Pulmonary disease caused by Mycobacterium chelonae in a heart-lung transplant recipient with obliterative bronchiolitis. Am Rev Respir Dis: 1989; 140 3 802 805
289. Baldi S., Rapellino M., Ruffini E., Cavallo A., Mancuso M. Atypical mycobacteriosis in a lung transplant recipient. Eur Respir J: 1997; 10 4 952 954
290. Gilljam M., Scherstén H., Silverborn M., Jönsson B., Ericsson Hollsing A. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros: 2010; 9 4 272 276
291. Robinson P. D., Harris K. A., Aurora P., Hartley J. C., Tsang V., Spencer H. Paediatric lung transplant outcomes vary with Mycobacterium abscessus complex species. Eur Respir J: 2013; 41 5 1230 1232
292. Aitken M. L., Limaye A., Pottinger P., et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med: 2012; 185 2 231 232
293. Knoll B. M., Kappagoda S., Gill R. R., et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis: 2012; 14 5 452 460
294. Zaidi S., Elidemir O., Heinle J. S., et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis: 2009; 11 3 243 248
295. Griffith D. E., Aksamit T. R. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis: 2012; 25 2 218 227
296. Colin A. A. Eradication of mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol: 2000; 30 3 267 268
297. Radhakrishnan D. K., Yau Y., Corey M., et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol: 2009; 44 11 1100 1106
298. Saiman L., Siegel J.; Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control: 2003; 31 (3, Suppl): S1 S62
299. Kendall B. A., Winthrop K. L. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med: 2013; 34 1 87 94
300. Bange F. C., Brown B. A., Smaczny C., Wallace R. J. Jr, Böttger E. C. Lack of transmission of mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis: 2001; 32 11 1648 1650
301. Bryant J. M., Grogono D. M., Greaves D., et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet: 2013; 381 9877 1551 1560
302. Davidson R. M., Reynolds P. R., Farias-Hesson E., Duarte R. S., Jackson M., Strong M. Genome Sequence of an Epidemic Isolate of Mycobacterium abscessus subsp. bolletii from Rio de Janeiro, Brazil. Genome announcements: 2013; 1
303. Tettelin H., Davidson R. M., Agrawal S., et al. High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaks. Emerg Infect Dis: 2014; 20 3 364 371
304. Manuel O., Kumar D., Singer L. G., Cobos I., Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant: 2008; 27 1 11 16
305. Clark N. M., Lynch J. P. III, Sayah D., Belperio J. A., Fishbein M. C., Weigt S. S. DNA viral infections complicating lung transplantation. Semin Respir Crit Care Med: 2013; 34 3 380 404
306. Lehto J. T., Halme M., Tukiainen P., Harjula A., Sipponen J., Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant: 2007; 26 1 41 47
307. Weigt S. S., Gregson A. L., Deng J. C., Lynch J. P. III, Belperio J. A. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med: 2011; 32 4 471 493
308. Chamnan P., Shine B. S., Haworth C. S., Bilton D., Adler A. I. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care: 2010; 33 2 311 316
309. Moran A., Dunitz J., Nathan B., Saeed A., Holme B., Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care: 2009; 32 9 1626 1631
310. Milla C. E., Billings J., Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care: 2005; 28 9 2141 2144
311. Moran A., Brunzell C., Cohen R. C., et al. CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care: 2010; 33 12 2697 2708
312. Hadjiliadis D., Madill J., Chaparro C., et al. Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation. Clin Transplant: 2005; 19 6 773 778
313. Hofer M., Schmid C., Benden C., et al. Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation. J Cyst Fibros: 2012; 11 2 131 136
314. Heisel O., Heisel R., Balshaw R., Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant: 2004; 4 4 583 595
315. Aris R. M., Neuringer I. P., Weiner M. A., Egan T. M., Ontjes D. Severe osteoporosis before and after lung transplantation. Chest: 1996; 109 5 1176 1183
316. Donovan D. S. Jr, Papadopoulos A., Staron R. B., et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med: 1998; 157 6, Pt 1 1892 1899
317. Cahill B. C., O'Rourke M. K., Parker S., Stringham J. C., Karwande S. V., Knecht T. P. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation: 2001; 72 7 1251 1255
318. Legroux-Gérot I., Leroy S., Prudhomme C., et al. Bone loss in adults with cystic fibrosis: prevalence, associated factors, and usefulness of biological markers. Joint Bone Spine: 2012; 79 1 73 77
319. Sheikh S., Gemma S., Patel A. Factors associated with low bone mineral density in patients with cystic fibrosis. J Bone Miner Metab: 2014
320. Hecker T. M., Aris R. M. Management of osteoporosis in adults with cystic fibrosis. Drugs: 2004; 64 2 133 147
321. Spira A., Gutierrez C., Chaparro C., Hutcheon M. A., Chan C. K. Osteoporosis and lung transplantation: a prospective study. Chest: 2000; 117 2 476 481
322. Aris R. M., Renner J. B., Winders A. D., et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med: 1998; 128 3 186 193
323. Aris R. M., Lester G. E., Renner J. B., et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med: 2000; 162 3, Pt 1 941 946
324. Conwell L. S., Chang A. B. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev: 2014; 3 CD002010
325. Gelfond D., Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol: 2013; 11 4 333 342, quiz e30-e31
326. Borowitz D., Gelfond D. Intestinal complications of cystic fibrosis. Curr Opin Pulm Med: 2013; 19 6 676 680
327. Shah N., Tan H. L., Sebire N., Suri R., Leuven K. The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients. Pediatr Pulmonol: 2013; 48 12 1181 1189
328. Pauwels A., Blondeau K., Dupont L. J., Sifrim D. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis. Am J Gastroenterol: 2012; 107 9 1346 1353
329. Gilljam M., Chaparro C., Tullis E., Chan C., Keshavjee S., Hutcheon M. GI complications after lung transplantation in patients with cystic fibrosis. Chest: 2003; 123 1 37 41
330. Young L. R., Hadjiliadis D., Davis R. D., Palmer S. M. Lung transplantation exacerbates gastroesophageal reflux disease. Chest: 2003; 124 5 1689 1693
331. Lubetkin E. I., Lipson D. A., Palevsky H. I., et al. GI complications after orthotopic lung transplantation. Am J Gastroenterol: 1996; 91 11 2382 2390
332. Benden C., Aurora P., Curry J., Whitmore P., Priestley L., Elliott M. J. High prevalence of gastroesophageal reflux in children after lung transplantation. Pediatr Pulmonol: 2005; 40 1 68 71
333. Subhi R., Ooi R., Finlayson F., et al. Distal intestinal obstruction syndrome in cystic fibrosis: presentation, outcome and management in a tertiary hospital (2007-2012). ANZ J Surg: 2014; 84 10 740 744
334. Farrelly P. J., Charlesworth C., Lee S., Southern K. W., Baillie C. T. Gastrointestinal surgery in cystic fibrosis: a 20-year review. J Pediatr Surg: 2014; 49 2 280 283
335. Parisi G. F., Di Dio G., Franzonello C., et al. Liver disease in cystic fibrosis: an update. Hepat Mon: 2013; 13 8 e11215
336. Herrmann U., Dockter G., Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol: 2010; 24 5 585 592
337. Bhardwaj S., Canlas K., Kahi C., et al. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. J Clin Gastroenterol: 2009; 43 9 858 864
338. Pokorny C. S., Bye P. T., MacLeod C., Selby W. S. Antibiotic-associated colitis and cystic fibrosis. Dig Dis Sci: 1992; 37 9 1464 1468
339. Rivlin J., Lerner A., Augarten A., Wilschanski M., Kerem E., Ephros M. A. Severe Clostridium difficile-associated colitis in young patients with cystic fibrosis. J Pediatr: 1998; 132 1 177 179
340. Mylonakis E., Ryan E. T., Calderwood S. B. Clostridium difficile-Associated diarrhea: A review. Arch Intern Med: 2001; 161 4 525 533
341. Lee J. T., Hertz M. I., Dunitz J. M., et al. The rise of Clostridium difficile infection in lung transplant recipients in the modern era. Clin Transplant: 2013; 27 2 303 310
342. Nagakumar P. Pseudomembranous colitis in cystic fibrosis. Paediatr Respir Rev: 2013; 14 01 26 27
343. Yates B., Murphy D. M., Fisher A. J., et al. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. BMJ Case Rep: 2009; 2009 xx
344. Madill J., Gutierrez C., Grossman J., et al. Toronto Lung Transplant Program. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant: 2001; 20 3 288 296
345. Singer L. G., Brazelton T. R., Doyle R. L., Morris R. E., Theodore J.; International Lung Transplant Database Study Group. Weight gain after lung transplantation. J Heart Lung Transplant: 2003; 22 8 894 902
346. Hollander F. M., van Pierre D. D., de Roos N. M., van de Graaf E. A., Iestra J. A. Effects of nutritional status and dietetic interventions on survival in Cystic Fibrosis patients before and after lung transplantation. J Cyst Fibros: 2014; 13 2 212 218
347. Armitage J. M., Kormos R. L., Stuart R. S., et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant: 1991; 10 6 877 886, discussion 886-887
348. Randhawa P. S., Jaffe R., Demetris A. J., et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med: 1992; 327 24 1710 1714
349. Cohen A. H., Sweet S. C., Mendeloff E., et al. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med: 2000; 161 (4, Pt 1): 1252 1255
350. Aris R. M., Maia D. M., Neuringer I. P., et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med: 1996; 154 (6, Pt 1): 1712 1717
351. Kotloff R. M., Ahya V. N. Medical complications of lung transplantation. Eur Respir J: 2004; 23 2 334 342
352. Maisonneuve P., FitzSimmons S. C., Neglia J. P., Campbell P. W. III, Lowenfels A. B. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst: 2003; 95 5 381 387
353. Maisonneuve P., Marshall B. C., Knapp E. A., Lowenfels A. B. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst: 2013; 105 2 122 129
354. Schöni M. H., Maisonneuve P., Schöni-Affolter F., Lowenfels A. B.; CF/CSG Group. Cancer risk in patients with cystic fibrosis: the European data. J R Soc Med: 1996; 89 27 38 43
355. Rousseau A., Monchaud C., Debord J., et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit: 2003; 25 1 28 35
356. Knoop C., Vervier I., Thiry P., et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation: 2003; 76 4 683 688
357. Brugière O., Thabut G., Castier Y., et al. Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients. Chest: 2003; 123 6 1832 1837
358. Aigner C., Jaksch P., Taghavi S., et al. Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases. J Heart Lung Transplant: 2008; 27 1 60 65
359. Kawut S. M., Lederer D. J., Keshavjee S., et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med: 2008; 177 1 114 120